Cart
sales@molnova.com
Rhodblock 6
CAS No. 886625-06-5
Rhodblock 6( —— )
Catalog No. M34126 CAS No. 886625-06-5
Rhodblock 6 is a Rho kinase (ROCK) inhibitor that specifically inhibits Rho kinase activity and the localization of phosphorylated MRLC (Myosin Regulatory Light Chain).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 43 | In Stock |
|
| 10MG | 68 | In Stock |
|
| 25MG | 145 | In Stock |
|
| 50MG | 210 | In Stock |
|
| 100MG | 299 | In Stock |
|
| 200MG | 421 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRhodblock 6
-
NoteResearch use only, not for human use.
-
Brief DescriptionRhodblock 6 is a Rho kinase (ROCK) inhibitor that specifically inhibits Rho kinase activity and the localization of phosphorylated MRLC (Myosin Regulatory Light Chain).
-
DescriptionRhodblock 6 is a Rho kinase (ROCK) inhibitor that inhibits phospho-MRLC (myosin regulatory light chain) localization.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetROCK
-
RecptorROCK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number886625-06-5
-
Formula Weight215.25
-
Molecular FormulaC12H13N3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C(=O)C1CCC1)C=2C=C3C(=CC2)NN=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Adam B Castoreno, et al. Small molecules discovered in a pathway screen target the Rho pathway in cytokinesis. Nat Chem Biol. 2010 Jun;6(6):457-63. ?
molnova catalog
related products
-
RKI-1447
RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.
-
CAY10746
CAY10746 is a selective Rho kinase (ROCK) inhibitor, targeting ROCK I and ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively.
-
Cucurbitacin A
Cucurbitacin I, cytotoxic triterpenoid sterols isolated from plants, elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-Kinase.
